Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531768 | NSE Symbol : POLYMED | ISIN : INE205C01021 | Industry : Healthcare |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
27-Jan-2025	03-Feb-2025	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve The Company informed the Exchange about the Board Meeting to be held on 03rd February 2025. Pursuant to the Regulation 30 of SEBI(LODR) Regulations, 2015, Company has informed about the outcome of the Board Meeting held on today i.e. 03rd February, 2025. The Company has informed about the Unaudited Financial Results ( Standalone & Consolidated ) for the Third quarter and nine months ended on 31st December, 2024 (As per BSE Announcement Dated on 03/02/2025)
19-Oct-2024	28-Oct-2024	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve The Company informed the Exchange about the upcoming Board Meeting Scheduled to be held on 28th October 2024 The Company has informed the exchange about the outcome of the Board Meeting held on today i.e. 28th October, 2024. (As Per BSE Announcement dated on 28.10.2024)
17-Jul-2024	22-Jul-2024	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2024 inter alia to consider and approve Dear Sir/Madam Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that a meeting of the Board of Director of the Company will be held on Monday the 22nd July 2024 inter alia to consider the following: a. To consider and approve the Unaudited Financial Results (Consolidated & Standalone) of the company for the First Quarter ended 30th June 2024. b. To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window vide letter dated 29th June 2024 the Trading Window for dealing in securities of the company shall remain closed till 24th July 2024. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 22nd July, 2024 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the first quarter ended on 30th June 2024. b) To Re-appoint and Ratification of Remuneration of M/s. Jai Prakash & Company, Cost Accountants as Cost Auditors of the Company for the Financial Year 2024-25, subject to the approval of the shareholders in the forthcoming Annual General Meeting. c) To appoint Mr. Vimal Bhandari (DIN 0001318), as Non-Executive and Independent Director on the Board of the Company, subject to shareholder approval in upcoming Annual general meeting (As per BSE Announcement Dated on 22/07/2024)
25-Jun-2024	29-Jun-2024	Raising funds through Debt Instr.	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2024 inter alia to consider and approve Pursuant to Regulation 29(1) and 29(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 in continuation with our Board Meeting held on 08th March 2024 in which Board has approved Raising of funds intimation is hereby given that a Meeting of Board of Directors is scheduled to be held on Saturday the 29th June 2024 inter alia to consider and finalize the terms and condition and approve the modes of fund raising. Further in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys code of Conduct for Prevention of Insider Trading the Trading Window for dealings in the Companys securities will be closed till further notice. The Board would also consider convening an extra-ordinary general meeting/ postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal of fund raising as required. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 29th June, 2024, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase -III, New Delhi- 110020, has considered and approved the proposal for raising of funds through issuance of new securities by way Qualified Institutional Placement ('QIP') and seeking approval of the members by way of Special Resolution for the same and in this regard we wish to submit as under :- a) The Board has considered and approved raising of funds to the tune of amount not exceeding INR 1,000 Crore (One Thousand Crore) through new issue of equity shares by way of qualified institutions placement, in accordance with the relevant provisions of applicable law and subject to approval of the Company''s shareholders and receipt of applicable regulatory approvals. (As Per BSE Announcement Dated on 29.06.2024)
02-May-2024	17-May-2024	Accounts	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve Dear Sir/Madam Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that a meeting of the Board of Director of the Company will be held on Friday the 17th May 2024 inter alia to consider the following: a. To consider and approve the Audited Financial Results (Consolidated & Standalone) of the company for the financial year ended on 31st March 2024. b. To consider recommendation of Final Dividend If any on the Equity Shares for the Financial year ended on 31st March 2024. c. To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window vide letter dated 31st March 2024 the Trading Window for dealing in securities of the company shall remain closed till 19th May 2024. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 17th May, 2024, at Crowne Plaza Today, Plot No.1, Community Centre, Okhla -I, New Delhi-110020, approved the following businesses: a. Audited Financial Results (Consolidate & Standalone) for the Fourth quarter and financial year ended on 31st March 2024. b. Recommendation of Dividend of Rs. 3 (Three Rupees) per Equity Shares (60%) of Rs. 5 each for the Financial Year 2023-24, subject to the approval of shareholders. c. Any Other Item. The Meeting was started at 10.30 am and concluded on 1:30 pm. Kindly take a note of the same for your further needful and oblige us. (As Per BSE Announcement Dated on 17/05/2024)
04-Mar-2024	08-Mar-2024	Raising funds through Debt Instr.	POLY MEDICURE LIMITED has informed BSE about Board Meeting to be held on 08 Mar 2024 to consider Fund raising / Other business. POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/03/2024 ,inter alia, to consider and approve We wish to inform you that pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the board of directors (the 'Board') of the Poly Medicure Limited (the 'Company') is scheduled to be held on Friday, March 8, 2024 at 10:00 a.m. through video - conferencing facility to inter alia consider the following:- a) Business Plan for Financial Year 2024-25. b) consider and evaluate a proposal for raising of funds, in one or more tranches, through permissible mode(s) and / or combination(s) thereof as may be considered appropriate, by way of raising of debts, issuance of any instruments or securities, through private placement, preferential issue, rights issue, qualified institutions placement or such other methods or combinations thereof as may be decided by the Board, subject to such approvals as may be required, and to transact other businesses with the permission of the Chairperson. (As Per BSE Announcement Dated on 04.03.2024) Dear Sir/Madam, Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 8th March , 2024, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020 has considered and approved the following businesses:- a) Raising of funds for an aggregate amount not exceeding Rs. 800 Crore (Rupees Eight Hundred Crore only) in one or more tranches, through permissible mode(s) and / or combination(s) thereof as may be considered appropriate, by way of raising of debts, issuance of any instruments or securities, through private placement, preferential issue, rights issue, qualified institutions placement or such other methods or combinations thereof as may be decided by the Board, subject to such approvals as may be required. Read less.. (As Per BSE Announcement Dated on 08.03.2024)
19-Jan-2024	31-Jan-2024	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve Pursuant to the provisions of Regulation 29(1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that the meeting of the Board of Directors of the Company will be held on Wednesday the 31st day of January 2024 inter-alia to consider the following: To consider and approve Standalone and Consolidated Un-audited IND-AS compliant Financial Results along with Limited Review Report for the quarter and Nine Months ended on 31st December 2023 pursuant to regulation 33 of Listing Obligation and Disclosure Requirement 2015. To transact any other matter which the Board may deem fit. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 31st January, 2024, at registered office at 232-B, 3rd floor, Okhla industrial estate, PHASE-III, New Delhi -110020, approved the following businesses: a. On recommendation of Nomination Remuneration Committee approve the reappointment of Shri Dhruv Baid as Senior Manager, International Business Development for Five years with effect from 1st April 2024. b. Nomination & Remuneration Committee, has allotted 26,375 shares having face value of Rs 5/- each to its eligible employees of the Company who has exercise the option Under its Employee Stock Option Scheme, 2020. c. Unaudited Financial Results (Consolidate & Standalone) for the Third quarter and Nine months ended on 31st December 2023. d. Adoption of New set of Article of Association of the Company. e. Any Other Item. (As Per BSE Announcement Dated on: 31/01/2024)
25-Oct-2023	04-Nov-2023	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve Pursuant to the provisions of Regulation 29(1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that the meeting of the Board of Directors of the Company will be held on Saturday the 4th day of November 2023 inter-alia to consider the following: To consider and approve Standalone and Consolidated Un-audited IND-AS compliant Financial Results along with Limited Review Report for the quarter and half year ended on 30th September 2023 pursuant to regulation 33 of Listing Obligation and Disclosure Requirement 2015. To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window the Trading Window for dealing in securities of the Company shall remain closed till 6th August 2023. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 04th November, 2023, at Crowne Plaza Today , Plot No. 1, Community Centre, Okhla-I, New Delhi - 110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the Second quarter and half year ended on 30th September 2023. b) Any Other Item. The Meeting was started at 10.30 am and concluded on 1:30 pm. Kindly take a note of the same for your further needful and oblige us. Pursuant to Regulations 30 and 33 of SEBI(LODR) Regulations, 2015, we are pleased to inform to the stock exchnage that the Board of directors at their meeting held today i.e. 04th November, 2023 approved the Unaudited Financial Results ( Consolidated & Standalone) fo rthe second quarter and half year ended on 30th September, 2023. (As Per BSE Announcement dated on 04.11.2023)
26-Jul-2023	07-Aug-2023	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve Pursuant to the provisions of Regulation 29(1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that the meeting of the Board of Directors of the Company will be held on Monday the 7th day of August 2023 inter-alia to consider the following: To consider and approve Standalone and Consolidated Un-audited IND-AS compliant Financial Results along with Limited Review Report for the quarter ended 30 June 2023 pursuant to regulation 33 of Listing Obligation and Disclosure Requirement 2015. To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window the Trading Window for dealing in securities of the Company shall remain closed till 9th August 2023. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 07th August, 2023, at Polycon House A-27 & B-64, Industrial Estate, Bais Godam, Jaipur, Rajasthan - 302006, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the first quarter ended on 30th June 2023. b) Ratification of Remuneration to M/ s. Jai Prakash & Company, Cost Accountants appointed as Cost Auditors of the Company for the Financial Year 2023-24, subject to the approval of the shareholders in the forthcoming Annual General Meeting. c) Any other item. The meeting started at 10:30 am and concluded at 12:00 pm. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to infor m the stock exchang that the Board of Directors at their meeting held today i.e. 07th August, 2023, at polycon house, A-27 & B-64, Industrial Esate, Bais Godam, Jaipur, Rajasthan- 302006, approved the following business. Unaudited Financial Results (Consolidated & Standalone) for the first quarter ended on 30th June, 2023. (As Per BSE Announcement Dated on 07/08/2023)
29-Apr-2023	09-May-2023	Accounts	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2023 inter alia to consider and approve a) the Audited Financial Results (Consolidated & Standalone) of the Company for the financial year ended on 31st March 2023. b) recommendation of Final Dividend if any on the Equity Shares for the financial year ended on 31st March 2023. c) any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window vide letter dated 31st March 2023 the Trading Window for dealing in securities of the Company shall remain closed till 11th May 2023. This is for your information and record. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e.09th May, 2023, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Audited Financial Results (Consolidate & Standalone) for the year ended on 31st March 2023. b) Recommendation of Dividend of Rs. 3 (Three Rupees) per Equity Shares (60%) of Rs. 5 each for the Financial Year 2022-23, subject to the approval of shareholders. The meeting commenced at 10.30 a.m. and concluded at 12.30 p.m. Kindly take a note of the same for your further needful and oblige us. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e.09th May, 2023, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Audited Financial Results (Consolidate & Standalone) for the year ended on 31st March 2023. b) Recommendation of Dividend of Rs. 3 (Three Rupees) per Equity Shares (60%) of Rs. 5 each for the Financial Year 2022-23, subject to the approval of shareholders. The meeting commenced at 10.30 a.m. and concluded at 12.30 p.m. Kindly take a note of the same for your further needful and oblige us. (As Per BSE Announcement Dated on 09.05.2023)
17-Jan-2023	28-Jan-2023	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2023 inter alia to consider and approve Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Saturday the 28th January 2023 inter alia to consider the following: a) To consider and approve the Un-Audited Financial Results of the Company for the Third quarter and Nine months ended on 31st December 2022. b) To transact any other matter which the Board may deem fit. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 28th January, 2023, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses a) Unaudited Financial Results (Consolidate & Standalone) for the Third quarter and nine months ended on 31st December 2022. b) Constituted a Banking Operations Committee of the Company for the purpose of smooth functioning of the business operations of the Company. c) Any Other Item. Please note that the Board Meeting was started at 10.30 AM and concluded at 12:15 PM. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 28th January, 2023, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses a) Unaudited Financial Results (Consolidate & Standalone) for the Third quarter and nine months ended on 31st December 2022. b) Constituted a Banking Operations Committee of the Company for the purpose of smooth functioning of the business operations of the Company. c) Any Other Item. Please note that the Board Meeting was started at 10.30 AM and concluded at 12:15 PM. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, in addition to the outcome of Board Meeting given today, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today, have passed a resolution for allotment of 52,500 equity shares of face value of Rs. 5/- each, to the Eligible Employees of the Company, who have exercised their Options. These shares shall rank pari-passu with the existing equity shares of the Company in all respects. (As Per BSE Announcement Dated on 28.01.2023)
19-Oct-2022	04-Nov-2022	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2022 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday the 4th November 2022 inter alia to consider the following: a) To consider and approve the Standalone and Consolidated Un-Audited Financial Results of the Company for the Second quarter and half year ended on 30th September 2022. b) To transact any other matter which the Board may deem fit. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 04th November, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the Second quarter and half year ended on 30th September 2022. b) Any Other Item. (As Per BSE Announcement dated on 04.11.2022) Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 04th November, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the Second quarter and half year ended on 30th September 2022. b) Any Other Item. The Meeting was started at 10.30 am and concluded on 12:15 pm. (As Per BSE Announcement Dated 05.11.2022)
25-Jul-2022	04-Aug-2022	Quarterly Results	Quarterly Results POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 ,inter alia, to consider and approve Standalone and Consolidated Un-audited IND-AS compliant Financial Results along with Limited Review Report for the quarter ended 30 June, 2022 pursuant to regulation 33 of Listing Obligation and Disclosure Requirement, 2015. To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window, the Trading Window for dealing in securities of the Company shall remain closed till 6th August, 2022. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 04th August, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the first quarter ended on 30th June 2022. b) Allotted 18,050 Equity Shares of Rs. 5 each, pursuant to exercise of an option under Employee Stock Option Scheme, 2016. c) Ratification of Remuneration to M/ s. Jai Prakash & Company, Cost Accountants appointed as Cost Auditors of the Company for the Financial Year 2022-23, subject to the approval of the shareholders in the forthcoming Annual General Meeting. d) Resolution for Shareholders approval for re-appointment and remuneration of Mr. Vishal Baid as Sr. President (Sales and Marketing), of the Company, in the forthcoming Annual General Meeting. Site optimized for IE9 & above. : Disclaimer : Website Policies : Privacy Policy : Sitemap Copyright c BSE Ltd. All Rights Reserved. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 04th August, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the first quarter ended on 30th June 2022. (As Per BSE Announcement Dated 04.08.2022)
11-May-2022	24-May-2022	Final Dividend	Final Dividend & Audited Results Poly Medicure Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 24, 2022, inter alia, has recommended Dividend of Rs. 2.5 (Two and half Rupees) per Equity Shares (50%) of Rs. 5 each for the Financial Year 2021-22, subject to the approval of shareholders. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 24th May, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Audited Financial Results (Consolidate & Standalone) for the year ended on 31st March 2022. b) Recommendation of Dividend of Rs. 2.5 (Two and half Rupees) per Equity Shares (50%) of Rs. 5 each for the Financial Year 2021-22, subject to the approval of shareholders. (As Per BSE Announcement Dated on 24.05.2022)
18-Jan-2022	31-Jan-2022	Quarterly Results	POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 inter alia to consider and approve Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday the 31st January 2022 inter alia to consider the following: a) To consider and approve the Un-Audited Financial Results of the Company for the Third quarter and Nine months ended on 31st December 2021. b) To transact any other matter which the Board may deem fit. Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 31st January, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) alongwith Limited Review Report for the third quarter and nine months ended on 31st December 2021; and b) Any Other businesses. Kindly take a note of the same for your further needful and oblige us. Thanking You, (As Per BSE Announcement Dated on 31.01.2022)

1 2

LOGIN HERE

Poly Medicure Ltd

Board Meeting